![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Takeda’s Zika Vaccine Candidate Fast-Tracked by FDA
Takeda’s Zika Vaccine Candidate Fast-Tracked by FDA
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
February 1, 2018
Japanese drugmaker Takeda received a fast-track designation from the FDA for its Zika virus vaccine candidate, TAK-426.
The fast-track designation was given to expedite the development and review process, as there are currently no medicines or vaccines for the virus.
The candidate is currently in a Phase 1 trial under an investigational new drug application. If the results of the trial are supportive, Takeda plans to move into Phase 2 development as soon as possible.
Upcoming Events
-
21Oct